| Literature DB >> 33887322 |
Abstract
A year ago when I first contemplated writing this article, my intent was to provide a detailed review of the contributions of the diverse community of talented scientists in my lab to the nuclear receptor research field. In the throes of a deadly pandemic, political turmoil, and Black Lives Matter, however, I found myself compelled to tell a more personal story. While I will still cover milestones in our understanding of the intracellular trafficking of the thyroid hormone receptor, now these will be set against the backdrop of my path as a woman in STEM and on being intentionally inclusive. By sharing reflections on my journey, I hope to encourage young investigators to persist in their pursuit of a career in science.Entities:
Keywords: acetylation; intracellular trafficking; nuclear receptor; nuclear translocation; thyroid hormone
Year: 2021 PMID: 33887322 PMCID: PMC8134074 DOI: 10.1016/j.jbc.2021.100677
Source DB: PubMed Journal: J Biol Chem ISSN: 0021-9258 Impact factor: 5.157
Figure 1The author at age 6 with her toy waffle breakfast set.
Figure 2Thyroid hormone receptor (TR) nucleocytoplasmic shuttling pathway. The well-characterized pathway for TRα1 elucidated by our lab is depicted. TRα1 binds to specific importins in the cytoplasm, as indicated. The TRα1–importin complex passes through a nuclear pore complex (NPC) embedded in the nuclear envelope into the nucleus, where the complex is disassembled and TRα1 binds to target genes. TRα1 exits the nucleus through the nuclear pore complex (NPC) in association with specific exportins or the calreticulin (CRT)/CRM1 (exportin 1) complex. TRβ1 follows a similar nucleocytoplasmic shuttling pathway, but nuclear import is solely mediated by the importin α1/importin β1 complex. TR activation involves a multifaceted cascade of events that culminates in binding DNA and modulation of target gene expression. TRs often heterodimerize with the retinoid X receptor (RXR). Corepressors, such as N-CoR1 and N-CoR2, and histone deacetylases, are bound to TR in the absence of ligand. Upon thyroid hormone (T3) binding, TR undergoes a conformational change, resulting in binding of a new set of activator proteins, such as mediator subunit MED1 and CBP/p300, a lysine acetyltransferase (KAT). Nonacetylated TRα1 and TRβ1 are primarily localized to the nucleus and have reduced intranuclear mobility, while the acetylated receptors have greater intranuclear mobility and localize to the cytoplasm. Acetylated receptors may be targeted for proteasome-mediated degradation or deacetylated by a sirtuin (SIRT) or lysine deacetylase (KDAC). The cellular compartment for TR deacetylation remains unknown (as indicated by the question marks).